The global healthcare industry is under severe stress to cope with the global demand for cures of thousands of diseases. These diseases are mainly caused by:
Realising the fact that global drug giants are unable to support the global healthcare industry, a low profile project was initiated by international investors in 1995. The primary objective is to identify rainforest bioactive compounds, which could help alleviate the sufferings of the 7.5 billion global populations from degenerative diseases.
The investors gathered scientists to collaborate in a project called RTM 2050. The vision of RTM 2050 is to work towards Changing the Landscape of Future Global Disease Treatment, Touching the Lives of Millions.
Malaysia was once known as the Golden Chersonese or Golden Peninsular by the Greek and Roman geographers. The endless list of natural resources shows that Malaysia is full of high value biodiversity and treasures. This is evidenced by its world’s oldest tropical rainforest, the 130 million year old Pahang National Park.
The RTM 2050 team started with screening the Malaysian biodiversity for bioactive compounds. This was not an easy task as they screened various biodiversity components including tropical plants, microbes, soil and aquatic animals. The team made huge discoveries that may help change the landscape of future global disease treatment.
Choosing the exotic Malaysian tropical rainforest and biodiversity is certainly a good starting point. However, it is still a long and winding road for the RTM 2050 initiative to reach its ultimate goal of changing the global landscape of future disease treatment. This is a journey of making big discoveries in helping millions of people especially those who suffer from degenerative diseases.
Concurrently, the team developed a process called Micro-7 Aerobio (“M-7A”) platform which is a specially designed fermentation process. This platform is capable of building a long pipeline of potential therapeutic bioactive compounds. Through this M-7A platform, the Cultured Coconut Concentrate (“C3”) has been developed.
They are convinced that the C3 has huge potential to become complimentary and adjunct therapy to various therapeutic application. Under the RTM 2050 initiative, the C3 has been subjected to various scientific research.
A low profile consumer pilot marketing programme was launched in year 2006 in Asia, America and European countries to intorduce the C3 as a powerful nutraceutical. This is to understand the direction of the technology in disease application and to gather global consumer feedback.
The outcome was over whelming as we have managed to collect thousands of testimonials that cover a broad range of therapeutic effects in various countries tested. The consumers agreed that C3 had helped in improving their quality of life. The RTM 2050 team is convinced that C3 is certainly a promising solution in combatting degenerative diseases in the future.